<DOC>
	<DOCNO>NCT00000628</DOCNO>
	<brief_summary>Part 1 : To study potential safety pharmacokinetic ( blood level ) effect zidovudine ( AZT ) L-697,661 ; obtain additional pharmacokinetic information human L-697,661 ; study effect L-697,661 hepatic enzyme induction . Part 2 : To begin study antiviral activity L-697,661 . L-697,661 newly identify compound inhibits HIV replication ( reproduction growth ) cell culture . It work together AZT HIV .</brief_summary>
	<brief_title>A Pharmacokinetic Study L-697,661 Alone Combination With Zidovudine</brief_title>
	<detailed_description>L-697,661 newly identify compound inhibits HIV replication ( reproduction growth ) cell culture . It work together AZT HIV . Part 1 : Twelve patient randomly assign one two group . Group 1 patient receive AZT 7 day , follow AZT plus L-697,661 food 56 day . Group 2 patient receive drug 7 day , follow L-697,661 food 56 day . Antipyrine administer 1 hour prior study drug day 8 , 22 , 35 . Part 2 : Fifteen patient receive L-697,661 food , 8 week . Therapy L-697,661 may extend beyond 8 week 24 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>L 697661</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection . Prior Medication : Included : Patients Part 1 must receive previous zidovudine ( AZT ) stable dose least 500 mg/day without evidence toxicity . Patients Part 2 must receive previous AZT = &gt; 300 mg/day &lt; 6 consecutive week within 1 year prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Acute HIVrelated opportunistic infection require ongoing treatment . Diarrhea define 3 liquid stools/day one week . Wilson 's Gilbert 's disease , porphyria , chronic acute hepatic disease . Potentially lifethreatening allergic reaction component zidovudine . Acute chronic medical condition opinion investigator would place patient risk participation study . Concurrent Medication : Excluded : Systemic bronchodilator , acetaminophen , aspirin . Prior Medication : Excluded : Didanosine ( ddI ) dideoxycytidine ( ddC ) within 14 day prior entry . Immune modulators investigational drug within 30 day prior entry . Drugs known induce hepatocellular enzyme , phenobarbital , phenytoin , warfarin , ketoconazole , oral contraceptive , within 30 day prior entry . Patients Part 2 : Excluded : Zidovudine within 4 week prior receive first dose study drug . Risk Behavior : Excluded : Patients investigator feel would comply study requirement . Patients may follow prior condition : Acute chronic medical condition opinion investigator would place patient risk participation study . Potentially lifethreatening allergic reaction component zidovudine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1994</verification_date>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>